Acesso livre
Acesso livre

Oncologia

M-A | Comparação entre desfechos de quimiorradioterapia neoadjuvante e quimioterapia neoadjuvante em pacientes com câncer esofágico localmente avançado.

8 Nov, 2021 | 12:24h

Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis – EClinicalMedicine


Estudo randomizado por cluster | Em idosos com câncer avançado, um programa de avaliação geriátrica reduziu os efeitos tóxicos do tratamento.

5 Nov, 2021 | 17:09h

Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study – The Lancet

Comunicado de imprensa: Less Chemotherapy, Personalized Care: Wilmot Study Reinforces Major Strides in Geriatric Oncology – University of Rochester Medical Center

Conteúdos relacionados:

RCT: A geriatric assessment–driven intervention can reduce chemotherapy-related toxic effects in older adults with cancer.

Perspective: A Cancer Care Approach Tailored to The Elderly May Have Better Results

 

Comentário da autora no Twitter (fio – clique para saber mais)

 


Diretriz do CDC | Pessoas imunocomprometidas podem precisar de uma quarta dose de vacina contra Covid-19.

4 Nov, 2021 | 12:05h

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Comentários:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News


Programa nacional de vacinação contra HPV na Inglaterra foi associado com uma redução estimada de 87% nas taxas de câncer do colo do útero naquelas que receberam a vacina entre 12-13 anos de idade.

4 Nov, 2021 | 11:59h

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Conteúdos relacionados:

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Comentário no Twitter

 


Atualização de Diretriz ASCO | Manejo de eventos adversos imunes relacionados a imunoterapia no tratamento do câncer.

2 Nov, 2021 | 12:25h

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update – Journal of Clinical Oncology


Diretriz ASCO | Manejo de eventos adversos imunes em pacientes sob terapia com célula T do receptor de antígeno quimérico.

2 Nov, 2021 | 12:23h

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline – Journal of Clinical Oncology


Revisão | Manejo clínico de lesões pancreáticas pré-malignas.

1 Nov, 2021 | 10:51h

Clinical Management of Pancreatic Premalignant Lesions – Gastroenterology


Revisão sistemática | Tratamento de eventos adversos imunológicos cutâneos em pacientes oncológicos sob imunoterapia.

29 Out, 2021 | 14:32h

Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review – JAMA Oncology (gratuito por tempo limitado)


Revisão sistemática | Antibióticos profiláticos para prevenir infecções por Gram-positivos associadas a cateter venoso central de longa permanência em adultos e crianças em tratamento oncológico.

28 Out, 2021 | 16:07h

Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer – Cochrane Library


Estudo randomizado | Daratumumabe, lenalidomida e dexametasona vs. lenalidomida e dexametasona isoladas no tratamento do mieloma múltiplo recém-diagnosticado.

28 Out, 2021 | 16:01h

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial – The Lancet Oncology

Comentário: Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma – The ASCO Post


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.